C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses

21 C.F.R. § 314.500 (2026)

Scope

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 3 IN 5Y cited 2008–2023 8citing cases
At a glance

Courts have cited this section in 8 opinions since 2008, 3 of them in the last five years.

This subpart applies to certain new drug products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).

[57 FR 58958, Dec. 11, 1992, as amended at 64 FR 402, Jan. 5, 1999]
The 8 cases that cite 21 C.F.R. § 314.500 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
REDAll. Hippocratic Med. v. FDA, 78 F.4th 210 (5th Cir. 2023).
cites § 314.500 4×cited by 24 cases
Reversed by FDA v. Alliance for Hippocratic Medicine (2024): the U.S. Supreme Court's own opinion in this case.
Where it cites § 314.500
“” 21 C.F.R. § 314.500 . And pregnancy is plainly not an illness.”
The case’s holding
An associational standing claim requires demonstrating a substantial risk of future injury to members through predictable and consistent agency policies.
Later courts cite it for
“all of this violates the comstock act.” · 3 citing courts
2
GREENJazz Pharm., Inc. v. Amneal Pharm., LLC, 895 F.3d 1347 (Fed. Cir. 2018).
cites § 314.500 1×cited by 22 cases
Where it cites § 314.500
“Because of its potential for abuse, the FDA approved Xyrem ® under "restricted distribution regulations contained in [ 21 C.F.R. § 314.500 ] (Subpart H) to assure safe use of the product.”
Later courts cite it for
“whether a reference qualifies as a 'printed publication' . . . is a legal conclusion based on underlying factual findings.” · 4 citing courts
cites § 314.500 1×cited by 63 cases
Where it cites § 314.500
“4 See 21 C.F.R. §§ 314.500 , 314.510. *40 In August 2000, Biogen and another company, Elan Pharma International Limited (“Elan”), announced that they had entered into a joint collaboration agreement to bring TYSABRI to market.”
The case’s holding
A statement is not intentionally misleading if the defendant lacks sufficient information at the relevant time to form an intent not to disclose certain information.
Later courts cite it for
“a statement cannot be intentionally misleading if the defendant did not have sufficient information at the relevant time to form an evaluation that there was a need to disclose certain information and to form an intent not to disclose it.” · 9 citing courts
4
GREENTummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).
cites § 314.500 1×cited by 7 cases
Where it cites § 314.500
“” 21 C.F.R. § 314.500 . The FDA amended 21 C.”
5
NO FLAGShareholder Rep. Servs. LLC v. Shire US Holdings, Inc., No. 2017-0863-KSJM (Del. Ch. Oct. 12, 2020).
cites § 314.500 2×cited by 0 cases
Where it cites § 314.500
“” JX-1698 ¶ 62 (citing 21 C.F.R. § 314.500 ); see 21 C.F.R. § 314.”
6
NO FLAGAll. Hippocratic Med. v. FDA, No. 23-10362, 2023 WL 2913725 (5th Cir. Apr. 12, 2023).
cites § 314.500 2×cited by 0 cases
Where it cites § 314.500
“” 21 C.F.R. § 314.500 . Originally, Subpart H was intended to promote rapid approval for life-saving HIV-AIDS drugs.”
7
GREENSeife v. Food & Drug Admin., 492 F. Supp. 3d 269 (S.D.N.Y. 2020).
cites § 314.500 1×cited by 0 casesunknown
Summary
No passage or summary on file for this case yet.
8
NO FLAGGenBioPro, Inc. v. Raynes, No. 3:23-cv-00058 (S.D. W. Va. May 2, 2023).
cites § 314.500 1×cited by 0 casesunknown
Where it cites § 314.500
“” 21 C.F.R. §§ 314.500 , 314.520; Compl. ¶ 36.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200820152023

One bar per year. Tallest: 3 cases in 2023. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
5th Cir.21st Cir.1Fed. Cir.1Del. Ch.1E.D.N.Y1S.D.N.Y.1S.D.W. Va1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com